GlobalData on MSN
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback